Financing to see Instylla through US Pivotal and other clinical trials BEDFORD, Mass., Oct. 14, 2020 /PRNewswire/ — Instylla, Inc., a privately held company developing minimally invasive liquid embolic products designed for use in peripheral vascular embolotherapy today announced closure of $25.4 million Series B financing. Participants in this latest round of financing included the new investors Excelestar Ventures, Catalyst… Read More »